Integra Lifesciences Holdings (IART) Cost of Revenue (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cost of Revenue data on file, last reported at $174.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 7.06% year-over-year to $174.9 million; the trailing twelve-month figure through Mar 2026 stood at $790.3 million (up 4.73% YoY), and the FY2025 full-year result was $803.6 million, up 10.32% from the prior year.
• Cost of Revenue declined to $174.9 million in Q1 2026, from $214.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $214.1 million in Q4 2025 to a low of $142.6 million in Q1 2022.
• A 5-year average of $173.6 million and a median of $174.2 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue rose 17.41% in 2023 and decreased 7.06% in 2026, its largest moves.
• Tracing IART's Cost of Revenue over 5 years: stood at $147.9 million in 2022, then climbed by 15.28% to $170.5 million in 2023, then gained by 13.5% to $193.6 million in 2024, then advanced by 10.58% to $214.1 million in 2025, then slipped by 18.28% to $174.9 million in 2026.
• Business Quant data shows IART's Cost of Revenue at $174.9 million in Q1 2026, $214.1 million in Q4 2025, and $195.1 million in Q3 2025.